^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BNT326

    i
    Other names: BNT326, YL202, BNT 326, YL 202, BNT-326, YL-202
    Associations
    News

    Trials

    Company:
    BioNTech, MediLink
    Drug class:
    Topoisomerase I inhibitor, HER3-targeted antibody-drug conjugate
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer (YL202-INT-101-01) (NCT05653752)
    Phase 1
    MediLink Therapeutics (Suzhou) Co., Ltd.
    Recruiting
    Last update posted :
    11/15/2024
    Initiation :
    12/20/2022
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    EGFR • HER-2
    |
    EGFR mutation • HR positive • HER-2 negative • EGFR L858R • EGFR exon 19 deletion • HR positive + HER-2 negative
    |
    BNT326
    A Study of YL202 in Selected Patients with Advanced Solid Tumors (NCT06107686)
    Phase 2
    MediLink Therapeutics (Suzhou) Co., Ltd.
    Recruiting
    Last update posted :
    11/15/2024
    Initiation :
    12/15/2023
    Primary completion :
    11/01/2026
    Completion :
    11/01/2028
    HER-2
    |
    HER-2 positive
    |
    BNT326